I don't think anybody would pretend, as you say, that the 27 member states of the European Union are all working in lockstep. There is something very important—and certainly rare disease patients are counting on it a lot—and that is the whole cross-border directive, that patients, if they cannot get the care in their own country, can in fact move and get the treatment from another country. I mean we're saying, “Good gosh, you can't even do that well across provinces in Canada”. That's the first thing we could learn, namely, how we actually facilitate patients who are in one jurisdiction getting access to what may be the only centre of excellence in another.
Quite frankly, as you might imagine, if there were in fact a national strategy, the provinces would expect that it would come with some sort of incentives to make it happen. I always hate to talk about the big word, in terms of funding, but I think there would need to be some sense of how we would do that. The same as CIHR has done, we need to have the Genome Canada kind of funding. Orphanet is funded out of a national budget. I do think that one would have to talk about how you would actually be able to mobilize the funding so that it could be centrally managed and to make sure that there is, in fact, fair participation, and not just based on population and ability to pay. We know that some of the pockets of these diseases are not necessarily in the most populous cities or even in the most populous provinces.